Financial firms (RBC, Citigroup, Morgan Stanley) issued rating and price target updates for 10X Genomics.
4 reports, 2 independent
Updated Oct 9
Gone quiet
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Financial firms (RBC, Citigroup, Morgan Stanley) issued rating and price target updates for 10X Genomics.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
10X Genomics
American biotechnology company
Nothing else this week.
-
Royal Bank of Canada
financial institution in Canada
-
Citigroup
American investment bank and financial services corporation
Related events
- Financial firms, including Jefferies, RBC, and Wells Fargo, issued rating and price objective updates for Biogen.
- Royal Bank of Canada, Citigroup, and Morgan Stanley issued price target and rating updates on August 27, 2026.
- Citigroup upped its price objective and gave a 'buy' rating, while Royal Bank of Canada reissued an 'outperform' rating for Abbott Laboratories.
- Royal Bank of Canada reiterated a sector perform rating for Lucid Group, Inc., with MarketBeat providing average rating and price target.
- Royal Bank of Canada reissued an outperform rating, while Citigroup downgraded Experian, and a board approved a share repurchase program.